“In the next one or two quarters, positive news flow on the pharma side, especially from the US, will start. Channel checks suggest that the pressure on pricing is reducing a lot. Most of the unviable smaller players are out of business. The market has consolidated into a few companies and people are identifying molecules which can have competitive edge,” says Daljeet Singh Kohli.